ECM
BLPH

ExodusPoint Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

ExodusPoint Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,500
Closed -$207K – 2450
2020
Q2 		$207K Buy
+16,500
New +$231K 0.01% 1507

Other funds holding BLPH

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's BLPH Position: Q3 2020 in Review

ExodusPoint Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2020, closing a stake of 16,500 shares — an estimated $207K sold.

ExodusPoint Capital Management first reported a position in BLPH in Q2 2020 and held it in 1 quarter. The position peaked at $207K in Q2 2020. 41 funds tracked by Wall St. Rank hold BLPH as of Q3 2020.

  • ExodusPoint Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • ExodusPoint Capital Management sold 16,500 Bellerophon Therapeutics, Inc. shares in Q3 2020, an estimated $207K.
  • ExodusPoint Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • ExodusPoint Capital Management's Bellerophon Therapeutics, Inc. position peaked at $207K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2020.

Based on ExodusPoint Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.